A new FDA approval gives some men with advanced prostate cancer another treatment option.

On July 31, 2026, the U.S. Food and Drug Administration (FDA) approved Pluvicto for some men whose prostate cancer has spread but still responds to hormone therapy.

Radioligand therapy (RLT) is one of the most exciting advances in precision cancer treatment. By combining a targeting molecule with a small amount of radiation, RLT delivers treatment directly to cancer cells while minimizing damage to surrounding healthy tissue.

Cribriform prostate cancer is a word pathologists use to describe how prostate cancer cells look under the microscope. The cells form large, sieve-like groups with tiny holes inside them. It is not a separate disease…